Regencell Bioscience Holdings Limited (RGC)

HK — Healthcare Sector
Peers: CYTK  MRUS  ATR  GRFS  ABVX  RYTM  STVN  AXSM  NUVL  MASI 

Automate Your Wheel Strategy on RGC

With Tiblio's Option Bot, you can configure your own wheel strategy including RGC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RGC
  • Rev/Share 0.0
  • Book/Share 0.5161
  • PB 22.3426
  • Debt/Equity 0.0
  • CurrentRatio 0.0
  • ROIC -0.2646

 

  • MktCap 5701457109.0
  • FreeCF/Share -0.154
  • PFCF -2845.7045
  • PE -80.895
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.2484

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
RGC
Published: November 24, 2025 by: The Motley Fool
Sentiment: Neutral

Regencell Bioscience looks like a risky bet. It's generated zero revenue for several years in a row.

Read More
image for news This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC
RGC
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC

About Regencell Bioscience Holdings Limited (RGC)

  • IPO Date 2021-07-16
  • Website https://www.regencellbioscience.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Yat-Gai Au
  • Employees 12
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.